Last Price$87.76NASDAQ Previous Close - Last Trade as of 3:59PM ET 10/19/20

Today's Change-2.87(3.17%)
Bid (Size)$87.00 (1)
Ask (Size)$89.89 (1)
Day Low / High$86.90 - 91.29

View Biotechnology IndustryPeer Comparison as of 10/19/2020


Incyte Corp ( NASDAQ )

Price: $87.76
Change: -2.87 (3.17%)
Volume: 32.00
3:59PM ET 10/19/2020

Immunomedics Inc ( NASDAQ )

Price: $87.61
Change: +0.05 (0.06%)
Volume: 4.2 M
3:59PM ET 10/19/2020

Alnylam Pharmaceuticals Inc ( NASDAQ )

Price: $140.64
Change: -4.76 (3.27%)
Volume: 20.00
3:59PM ET 10/19/2020

Exact Sciences Corp ( NASDAQ )

Price: $107.14
Change: +3.82 (3.70%)
Volume: 180.00
3:59PM ET 10/19/2020

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $77.33
Change: -1.92 (2.42%)
Volume: 1.2 M
3:59PM ET 10/19/2020

Read more news Recent News

Analyst Actions: BofA Securities Adjusts Incyte PT to $110 From $113, Maintains Buy Rating
11:47AM ET 10/15/2020 MT Newswires

Incyte (INCY) has an average rating of Outperform and price targets ranging from $87 to $139, according to analysts polled by Capital IQ. (MT Newswires...

Analyst Actions: Morgan Stanley Adjusts Incyte's Price Target to $103 From $100, Keeps Equal-Weight Rating
11:04AM ET 10/13/2020 MT Newswires

Incyte (INCY) has an average rating of outperform and price targets ranging from $87 to $139, according to analysts polled by Capital IQ. (MT Newswires...

Equities End Higher on Hopes Stimulus Deal Will Be Reached Amid Frantic Week of Talks
4:33PM ET 10/09/2020 MT Newswires

Stocks ended higher on Friday as officials fueled expectations that a stimulus deal will be reached to help Americans hurting financially by the continuing...

Incyte Strikes Deal to Use Nimble Therapeutics Platform for Drug Discovery
1:51PM ET 10/05/2020 MT Newswires

Nimble Therapeutics said on Monday it has struck a deal for Incyte (INCY) to use its proprietary peptide synthesis platform for drug development in return...

Company Profile

Business DescriptionIncyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE. View company web site for more details
Address1801 Augustine Cut-Off
Wilmington, Delaware 19803
Number of Employees1,367
Recent SEC Filing10/13/20204
Chairman, President & Chief Executive OfficerHervé Hoppenot
Chief Financial Officer & Executive Vice PresidentChristiana Stamoulis
Chief Medical Officer & Executive Vice PresidentSteven H. Stein
Chief Scientific Officer & Executive VPDashyant Dhanak

Company Highlights

Price Open$91.04
Previous Close$87.76
52 Week Range$62.48 - 110.37
Market Capitalization$19.2 B
Shares Outstanding218.7 M
SectorHealth Technology
Next Earnings Announcement11/03/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.93
Beta vs. S&P 500N/A
Revenue$1.9 B
Net Profit Margin-8.00%
Return on Equity-8.22%

Analyst Ratings as of 10/15/2020

Consensus RecommendationConsensus Icon
Powered by Factset